Zensar delivered a mixed performance in Q1FY27; Revenue grew a modest 1.1% QoQ CC to USD 159.5mn, powered by BFSI (+8.3% QoQ) and early ramp-up of the ~USD 210mn mega deal, while HLS, MCS and TMT continued to bleed (-2.3% to -9.1%), extending a two-quarter pattern of broad-based softness outside financial services. Margins contracted 150bps on pre-staffing costs for the large deal and elevated SG&A/travel spend, with management guiding flattish margins through Q2/Q3 before recovery from Q3FY27. Order book...